PharmaMar

PharmaMar stands at the forefront of biotechnology research, dedicated to pioneering advancements in oncology. Headquartered in Colmenar Viejo, Madrid, PharmaMar is committed to the discovery and development of innovative antitumor molecules inspired by the sea. The company's mission is to provide healthcare professionals with cutting-edge tools to effectively treat cancer.

PharmaMar boasts a robust oncology R&D program and a promising pipeline of drug candidates. Notably, the company develops and commercializes Yondelis® in Europe and is actively advancing clinical-stage programs for various solid cancers, including lurbinectedin (PM1183), PM184, and PM14. With subsidiaries spanning across Germany, Italy, France, Switzerland, Belgium, Austria, and the United States, PharmaMar operates with a global vision and reach. The primary address is Avda. De los Reyes, 1, Colmenar Viejo, Madrid 28770, ES.

Furthermore, PharmaMar wholly owns GENOMICA, a molecular diagnostics company, and Sylentis, a company focused on researching therapeutic applications of gene silencing (RNAi). PharmaMar continues to solidify its position as a world leader in the discovery of marine-derived antitumor drugs through unwavering commitment to research and patients. We invite the management of PharmaMar to create a customized and exclusive company showcase and product listing on our platform to further amplify your success.